CPSE:ZEALBiotechs
Zealand Pharma (CPSE:ZEAL) Is Up 22.7% After Earnings Swing From Loss to Net Income – Has The Bull Case Changed?
Zealand Pharma reported its third quarter 2025 results, announcing sales of DKK49.57 million and a quarterly net loss of DKK404.23 million, while nine-month sales reached DKK9.15 billion with net income of DKK6.83 billion.
This rapidly shifting financial picture shows a swing from net loss to substantial net income over the nine-month period, underlining the impact of recent commercial developments.
We'll now consider how Zealand's dramatic year-to-date earnings turnaround may influence the...